Technology explainer
How Do RAS Inhibitors Block Cancer Growth Signals?
RAS inhibitors target molecular switches that many tumours keep permanently active. Some lock a specific mutant form, while broader drugs block active RAS through a stabilised protein complex. Their benefit depends on tumour biology, resistance and the treatment setting.
Short answer: RAS inhibitors interfere with proteins that act as growth switches inside cells. In many cancers, a mutated RAS protein remains active and repeatedly tells the cell to grow. Different inhibitors either lock a particular mutant form in an inactive state or block the active protein from passing its signal onward.
Why RAS became an important cancer target
RAS proteins sit near the top of signalling networks that control growth and survival. Mutations in KRAS, NRAS or HRAS can keep those networks active without the normal external instruction. KRAS mutations are especially common in pancreatic ductal adenocarcinoma and also appear in colorectal and lung cancers.
Why the target was considered difficult
Many medicines work by fitting into a pocket on a protein. RAS has a relatively smooth surface and binds its natural molecules very tightly, leaving few obvious places for a drug to attach. Researchers eventually found small pockets that appear in particular mutant or activity states and designed molecules around them.
How different RAS inhibitors work
Mutant-selective inhibitors recognize one altered form, such as KRAS G12C, and trap it in a state that cannot send the growth signal. Broader RAS inhibitors can use a second molecule as part of a three-part complex, stabilizing an interaction that prevents active RAS from contacting downstream effectors. This approach is sometimes described as molecular glue.
What RAS inhibition does not guarantee
Blocking one pathway does not automatically eliminate a tumour. Cancer cells may contain several RAS variants, activate alternative signalling routes or acquire resistance. A drug that works in one tumour type or treatment line may not produce the same benefit in another. Clinical trials must therefore establish survival, safety and the exact patient group for each inhibitor.
What researchers are testing next
Current studies are combining RAS inhibitors with chemotherapy, immunotherapy and other targeted drugs, and are moving them into earlier treatment lines. The central questions are whether combinations delay resistance, whether toxicity remains manageable and which tumour features predict durable benefit.
First appeared in
A Pancreatic Cancer Drug That Doubled Median Survival Is Now Approved
